Whole-Body Vibration Treatment in Prostate Cancer Survivors on Androgen Suppression Therapy

The Effect of Whole-Body Vibration Treatment on Bone Metabolism in Prostate Cancer Survivors who are undergoing Androgen Suppression Therapy

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000082808

Enrollment

Registered

2012-01-17

Start date

2012-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to examine the effect of vibration therapy on markers of bone turnover in prostate cancer survivors on androgen suppression therapy. Who is it for? You may be eligible to join this study if you are a man currently taking an androgen suppression therapy for the treatment of prostate cancer. Trial details. Participants in this trial will be randomly (by chance) allocated to one of two groups. One group will undergo whole body vibration therapy. This involves standing on a gently vibrating platform for 20 minutes, three times per week over a period of 12 weeks. The other group will be assigned to no treatment for the 12 week trial period. After this time participants in this group will be offered the vibration treatment. Participants will give blood and urine samples at baseline and at 12 weeks to examine markers of bone metabolism. They will also complete some tests of physical function and questionnaires about fatigue, quality of life and physical activity levels at these time points. It is thought that vibration training will decrease the breakdown of bone compared to no training.

Interventions

Whole body vibration therapy (using a vibration device), 20 minutes, three times per week for 12 weeks. Vibration will be at 32-37Hz, 0.85mm peak-to-peak displacement, and at a magnitude of 0.3g.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Undergoing androgen suppression therapy for prostate cancer and are within one year of initiation of treatment. Willing to continue taking any bone altering medications or supplements they were previously taking for the duration of the study, including calcium and vitamin D. Able to stand unassisted for sustained periods of time (i.e. 20 minutes)

Exclusion criteria

Currently taking bisphosphonate medication; Cognitive impairment; Contraindications to vibration platform training (including pacemaker and fracture within the past six months); Diagnosis of bone metastasis; Diagnosis of diseases other than osteoporosis affecting bone

Outcome results